{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:46:42Z","timestamp":1794358002043,"version":"4.9.0"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32072925"],"award-info":[{"award-number":["32072925"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2662020DKPY020"],"award-info":[{"award-number":["2662020DKPY020"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.pharmthera.2023.108550","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:48:34Z","timestamp":1698673714000},"page":"108550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Multitarget antibacterial drugs: An effective strategy to combat bacterial resistance"],"prefix":"10.1016","volume":"252","author":[{"given":"Jin","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youle","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awais","family":"Ihsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guyue","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108550_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105923","article-title":"Emergent crisis of antibiotic resistance: A silent pandemic threat to 21st century","volume":"174","author":"Akram","year":"2023","journal-title":"Microbial Pathogenesis"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0010","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1093\/jac\/dky042","article-title":"Role of bacterial efflux pumps in biofilm formation","volume":"73","author":"Alav","year":"2018","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.watres.2023.119629","article-title":"Xenogenetic evolutionary of integrons promotes the environmental pollution of antibiotic resistance genes \u2014 Challenges, progress and prospects","volume":"231","author":"An","year":"2023","journal-title":"Water Research"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0020","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41579-019-0293-3","article-title":"Antibiotic development \u2014 Economic, regulatory and societal challenges","volume":"18","author":"\u00c5rdal","year":"2020","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0030","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/IDR.S173867","article-title":"Antibiotic resistance: A rundown of a global crisis","volume":"11","author":"Aslam","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jac\/dkt401","article-title":"Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: Safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses","volume":"69","author":"Baldoni","year":"2014","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065777","article-title":"Antibiotics and bacterial resistance-a short story of an endless arms race","volume":"24","author":"Baran","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0045","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/14656566.2015.983077","article-title":"Clinical, economic and societal impact of antibiotic resistance","volume":"16","author":"Barriere","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nature Reviews. Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0055","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/AAC.05532-11","article-title":"Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic","volume":"56","author":"Blais","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/430912","article-title":"Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials","volume":"41","author":"Bliziotis","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-018-0278-9","article-title":"Species-specific activity of antibacterial drug combinations","volume":"559","author":"Brochado","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0070","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tips.2015.08.010","article-title":"Polypharmacology shakes hands with complex aetiopathology","volume":"36","author":"Brodie","year":"2015","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0075","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/cmdc.202000858","article-title":"Systematic assessment of fragment identification for multitarget drug design","volume":"16","author":"Brunst","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0080","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3233\/JAD-201211","article-title":"A retrospective study on the benefits of combined citicoline, memantine, and acetylcholinesterase inhibitor treatments in older patients affected with Alzheimer\u2019s disease","volume":"79","author":"Castagna","year":"2021","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1568026621666211129140958","article-title":"Molecular modeling techniques applied to the design of multitarget drugs: Methods and applications","volume":"22","author":"Castro","year":"2022","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0090","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1039\/c2mb25110h","article-title":"Prediction of chemical-protein interactions: Multitarget-QSAR versus computational chemogenomic methods","volume":"8","author":"Cheng","year":"2012","journal-title":"Molecular BioSystems"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0095","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/femsre\/fux020","article-title":"Structure, function and regulation of Pseudomonas aeruginosa porins","volume":"41","author":"Chevalier","year":"2017","journal-title":"FEMS Microbiology Reviews"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0100","first-page":"600","article-title":"Bacterial RNA polymerase: A promising target for the discovery of new antimicrobial agents","volume":"8","author":"Chopra","year":"2007","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0105","first-page":"535","article-title":"Emtricitabine\/tenofovir (Truvada) for HIV prophylaxis","volume":"88","author":"Coutinho","year":"2013","journal-title":"American Family Physician"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0110","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nrmicro.2017.28","article-title":"Next-generation approaches to understand and combat the antibiotic resistome","volume":"15","author":"Crofts","year":"2017","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0115","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","article-title":"Molecular mechanisms of antibiotic resistance revisited","volume":"21","author":"Darby","year":"2023","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0120","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1021\/acs.jmedchem.8b01093","article-title":"Battle against vancomycin-resistant bacteria: Recent developments in chemical strategies","volume":"62","author":"Dhanda","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00077-17","article-title":"Antibiotic hybrids: The next generation of agents and adjuvants against gram-negative pathogens?","volume":"31","author":"Domalaon","year":"2018","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0130","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2174\/156802609789630947","article-title":"Quinolones: Action and resistance updated","volume":"9","author":"Drlica","year":"2009","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0135","series-title":"History, current situation, and future perspectives on antibiotics and antibiotic resistance","first-page":"109","volume":"Vol. 2","author":"Dyary","year":"2023"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/IDR.S55778","article-title":"Agriculture and food animals as a source of antimicrobial-resistant bacteria","volume":"8","author":"Economou","year":"2015","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0145","doi-asserted-by":"crossref","first-page":"12462","DOI":"10.3390\/ijms232012462","article-title":"Estimating the similarity between protein pockets","volume":"23","author":"Eguida","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800141","article-title":"Recent updates of fluoroquinolones as antibacterial agents","volume":"351","author":"Ezelarab","year":"2018","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0155","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0160","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00706-018-2215-x","article-title":"Modifications of quinolones and fluoroquinolones: Hybrid compounds and dual-action molecules","volume":"149","author":"Fedorowicz","year":"2018","journal-title":"Monatshefte fuer Chemie"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115040","article-title":"In vitro activity of TNP-2092 against periprosthetic joint infection-associated staphylococci","volume":"97","author":"Fisher","year":"2020","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0170","series-title":"Medicinal chemistry of chemotherapeutic agents","first-page":"67","article-title":"Chapter 3 - \u03b2-lactam antibiotics","author":"Fisher","year":"2023"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jiph.2016.08.007","article-title":"Antibiotic resistance","volume":"10","author":"Frieri","year":"2017","journal-title":"Journal of Infection and Public Health"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24050892","article-title":"The concept of an ideal antibiotic: Implications for drug design","volume":"24","author":"Gajd\u00e1cs","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105941","article-title":"Rational drug design strategies for the development of promising multi-target directed indole hybrids as anti-Alzheimer agents","volume":"127","author":"George","year":"2022","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0190","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: Aa systematic analysis for the Global Burden of Disease Study 2019","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0195","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Global burden of bacterial antimicrobial resistance in 2019: Aa systematic analysis","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0200","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2014.107","article-title":"Resistance to rifampicin: A review","volume":"67","author":"Goldstein","year":"2014","journal-title":"Journal of Antibiotics (Tokyo)"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0205","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijantimicag.2009.05.013","article-title":"Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa","volume":"34","author":"Gorgani","year":"2009","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0210","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1021\/acs.jmedchem.6b00867","article-title":"Hybrid antibiotic overcomes resistance in P. Aeruginosa by enhancing outer membrane penetration and reducing efflux","volume":"59","author":"Gorityala","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0215","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1021\/acsinfecdis.0c00001","article-title":"Multitarget approaches against multiresistant superbugs","volume":"6","author":"Gray","year":"2020","journal-title":"ACS Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0220","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1016\/j.jmb.2019.05.014","article-title":"Docking on lipid II\u2014A widespread mechanism for potent bactericidal activities of antibiotic peptides","volume":"431","author":"Grein","year":"2019","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/ijmr.IJMR_755_18","article-title":"Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids","volume":"149","author":"Gupta","year":"2019","journal-title":"The Indian Journal of Medical Research"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0230","first-page":"353","article-title":"Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: Sustained response in two patients with transfusion dependent thalassaemia","volume":"57","author":"Hamidah","year":"2002","journal-title":"The Medical Journal of Malaysia"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-019-05380-z","article-title":"Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer","volume":"178","author":"He","year":"2019","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0240","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1128\/AAC.01050-16","article-title":"Dual targeting of cell wall precursors by teixobactin leads to cell lysis","volume":"60","author":"Homma","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0245","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: The next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0250","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1016\/j.bmcl.2013.05.011","article-title":"Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors","volume":"23","author":"Hwang","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0255","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2174\/1568026619666190619115735","article-title":"Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases","volume":"19","author":"Ivasiv","year":"2019","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0260","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/tcr.202100014","article-title":"Fresh molecular concepts to extend the lifetimes of old antimicrobial drugs","volume":"21","author":"Jaber","year":"2021","journal-title":"Chemical Record"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0265","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1021\/jm5016846","article-title":"Clostridium difficile drug pipeline: Challenges in discovery and development of new agents","volume":"58","author":"Jarrad","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0270","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12866-016-0791-7","article-title":"Phenotypic and genotypic characterisation of multiple antibiotic-resistant Staphylococcus aureus exposed to subinhibitory levels of oxacillin and levofloxacin","volume":"16","author":"Jo","year":"2016","journal-title":"BMC Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106055","article-title":"Polypharmacology: The science of multi-targeting molecules","volume":"176","author":"Kabir","year":"2022","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0280","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/cmdc.201500599","article-title":"Structure-based virtual screening for dopamine D2 receptor ligands as potential antipsychotics","volume":"11","author":"Kaczor","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0285","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/bph.13664","article-title":"Targeting the hard to reach: Challenges and novel strategies in the treatment of intracellular bacterial infections","volume":"174","author":"Kamaruzzaman","year":"2017","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0290","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.2174\/0929867321666140303144625","article-title":"Multi-target drug design approaches for multifactorial diseases: From neurodegenerative to cardiovascular applications","volume":"21","author":"Katselou","year":"2014","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nbt1284","article-title":"Relating protein pharmacology by ligand chemistry","volume":"25","author":"Keiser","year":"2007","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0300","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1039\/C7NP00006E","article-title":"Bifunctional antimicrobial conjugates and hybrid antimicrobials","volume":"34","author":"Klahn","year":"2017","journal-title":"Natural Product Reports"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0305","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1126\/science.aaa4690","article-title":"Targeting DnaN for tuberculosis therapy using novel griselimycins","volume":"348","author":"Kling","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0310","first-page":"19688","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA): Burden of disease and control challenges in Europe","volume":"15","author":"K\u00f6ck","year":"2010","journal-title":"Euro Surveillance"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1158152","article-title":"Bifunctional antibiotic hybrids: A review of clinical candidates","volume":"14","author":"Koh","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0320","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2174\/1570159X16666180315141643","article-title":"Changing paradigm from one target one ligand towards multi-target directed ligand design for key drug targets of Alzheimer disease: An important role of in silico methods in multi-target directed ligands design","volume":"16","author":"Kumar","year":"2018","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0325","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1126\/science.352.6287.758","article-title":"Resistance fighters","volume":"352","author":"Kupferschmidt","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114078","article-title":"Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches \u2013 An overview","volume":"181","author":"Lai","year":"2022","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0335","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.drudis.2015.12.007","article-title":"In silico methods to address polypharmacology: Current status, applications and future perspectives","volume":"21","author":"Lavecchia","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0340","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(15)00474-2","article-title":"Access to effective antimicrobials: A worldwide challenge","volume":"387","author":"Laxminarayan","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0345","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019216","article-title":"Small but mighty: Cell size and bacteria","volume":"7","author":"Levin","year":"2015","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0350","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cell.2020.02.056","article-title":"The science of antibiotic discovery","volume":"181","author":"Lewis","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0355","article-title":"The human Kinome targeted by FDA approved multi-target drugs and combination products: A comparative study from the drug-target interaction network perspective","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0360","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/molecules25061375","article-title":"A review on applications of computational methods in drug screening and design","volume":"25","author":"Lin","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0365","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0370","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12941-022-00529-z","article-title":"Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis","volume":"21","author":"Liu","year":"2022","journal-title":"Annals of Clinical Microbiology and Antimicrobials"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0375","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01831-13","article-title":"Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of clostridium difficile infections","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0380","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/AAC.01830-13","article-title":"In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of clostridium difficile infections","volume":"58","author":"Locher","year":"2014","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0385","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/pharmaceutics14081749","article-title":"Fluoroquinolones hybrid molecules as promising antibacterial agents in the fight against antibacterial resistance","volume":"14","author":"Lungu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0390","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02930-19","article-title":"Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella pneumoniae","volume":"11","author":"Lv","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128648","article-title":"Discovery and structure\u2013activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors","volume":"65","author":"Lyons","year":"2022","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0400","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1021\/acs.jmedchem.6b00485","article-title":"Development of a dual-acting antibacterial agent (TNP-2092) for the treatment of persistent bacterial infections","volume":"59","author":"Ma","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0405","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10295-018-2109-2","article-title":"Discovery, properties, and biosynthesis of pseudouridimycin, an antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase","volume":"46","author":"Maffioli","year":"2019","journal-title":"Journal of Industrial Microbiology & Biotechnology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0410","doi-asserted-by":"crossref","first-page":"14319","DOI":"10.1016\/j.ijhydene.2022.02.175","article-title":"Green synthesis of DyBa2Fe3O7.988\/DyFeO3 nanocomposites using almond extract with dual eco-friendly applications: Photocatalytic and antibacterial activities","volume":"47","author":"Mahdi","year":"2022","journal-title":"International Journal of Hydrogen Energy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0415","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0420","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2666-5247(21)00173-7","article-title":"Rising antimicrobial resistance: An evolving epidemic in a pandemic","volume":"2","author":"Manesh","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0425","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2013.08.029","article-title":"Systems biology, complexity, and the impact on antiepileptic drug discovery","volume":"38","author":"Margineanu","year":"2014","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.005","article-title":"A dual-mechanism antibiotic kills gram-negative bacteria and avoids drug resistance","volume":"181","author":"Martin","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0435","first-page":"3","article-title":"Tackling threats and future problems of multidrug-resistant Bacteria","volume":"398","author":"Medina","year":"2016","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0440","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/14787210.2022.2122442","article-title":"Investigating forthcoming strategies to tackle deadly superbugs: Current status and future vision","volume":"20","author":"Mitra","year":"2022","journal-title":"Expert Review of Anti-Infective Therapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0445","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-030-28151-9_8","article-title":"Penicillin-binding proteins (PBPs) and bacterial cell wall elongation complexes","volume":"93","author":"Miyachiro","year":"2019","journal-title":"Sub-Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0450","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2174\/1568026622666220321124452","article-title":"Medicinal chemistry of inhibitors targeting resistant bacteria","volume":"22","author":"Monteiro","year":"2022","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0455","doi-asserted-by":"crossref","first-page":"9630","DOI":"10.1021\/acs.jmedchem.7b01064","article-title":"Novel linear lipopeptide paenipeptins with potential for eradicating biofilms and sensitizing gram-negative bacteria to rifampicin and clarithromycin","volume":"60","author":"Moon","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0460","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing multiple ligands - medicinal chemistry strategies and challenges","volume":"15","author":"Morphy","year":"2009","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0465","doi-asserted-by":"crossref","first-page":"E7077","DOI":"10.1073\/pnas.1611173113","article-title":"Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains","volume":"113","author":"M\u00fcller","year":"2016","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0470","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/bib\/bby078","article-title":"Binding site matching in rational drug design: Algorithms and applications","volume":"20","author":"Naderi","year":"2018","journal-title":"Briefings in Bioinformatics"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0475","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1568026623666230123142357","article-title":"Multi-target polypharmacology of 4-aminoquinoline compounds against malaria, tuberculosis and cancer","volume":"23","author":"Nandi","year":"2023","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1092556","article-title":"\u03b2-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward","volume":"13","author":"Narendrakumar","year":"2023","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0485","first-page":"131","article-title":"Towards effective consensus scoring in structure-based virtual screening","volume":"15","author":"Nhat Phuong","year":"2023","journal-title":"Interdisciplinary Sciences: Computational Life Sciences"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0490","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad120","article-title":"Machine learning for synergistic network pharmacology: A comprehensive overview","volume":"24","author":"Noor","year":"2023","journal-title":"Briefings in Bioinformatics"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0495","first-page":"E5726","article-title":"Directed evolution of multiple genomic loci allows the prediction of antibiotic resistance","volume":"115","author":"Nyerges","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0500","series-title":"The top 10 causes of death","author":"Organization, W. H","year":"2014"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0505","doi-asserted-by":"crossref","first-page":"16194","DOI":"10.1038\/nmicrobiol.2016.194","article-title":"Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids","volume":"2","author":"Pader","year":"2016","journal-title":"Nature Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0510","doi-asserted-by":"crossref","first-page":"S529","DOI":"10.1093\/cid\/ciz825","article-title":"The role of Iron and Siderophores in infection, and the development of Siderophore antibiotics","volume":"69","author":"Page","year":"2019","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0515","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.drudis.2012.01.003","article-title":"A series of case studies: Practical methodology for identifying antinociceptive multi-target drugs","volume":"17","author":"Pang","year":"2012","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0520","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, present, and future","volume":"55","author":"Papp-Wallace","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0525","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.2174\/0929867329666220922105615","article-title":"Multi-targeted HDAC inhibitors as anticancer agents: Current status and future prospective","volume":"30","author":"Patel","year":"2023","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0530","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/bmj.38028.520995.63","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials","volume":"328","author":"Paul","year":"2004","journal-title":"Bmj"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0535","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/ijms19041104","article-title":"Molecular consortia\u2014Various structural and synthetic concepts for more effective therapeutics synthesis","volume":"19","author":"Pawe\u0142czyk","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0540","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology \u2013 Foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0545","series-title":"Polypharmacology in drug discovery","first-page":"149","article-title":"Polypharmacological kinase inhibitors: New hopes for cancer therapy","author":"Petrelli","year":"2012"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0550","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106126","article-title":"Natural isoquinoline alkaloids: Pharmacological features and multi-target potential for complex diseases","volume":"177","author":"Plazas","year":"2022","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0560","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/jm900028n","article-title":"Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics","volume":"52","author":"Pokrovskaya","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0565","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design: A medicinal chemist\u2019s perspective on multitargeting compounds","volume":"62","author":"Proschak","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0570","first-page":"1258","article-title":"Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance","volume":"72","author":"Randall","year":"2017","journal-title":"The Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0575","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/17460441.2018.1413089","article-title":"Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery","volume":"13","author":"Ravikumar","year":"2018","journal-title":"Expert Opinion on Drug Discovery"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0580","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/eva.12808","article-title":"Five rules for resistance management in the antibiotic apocalypse, a road map for integrated microbial management","volume":"12","author":"Raymond","year":"2019","journal-title":"Evolutionary Applications"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0585","doi-asserted-by":"crossref","first-page":"9450","DOI":"10.3390\/s111009450","article-title":"Biosensor applications in the field of antibiotic research--a review of recent developments","volume":"11","author":"Reder-Christ","year":"2011","journal-title":"Sensors (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0590","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends in Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/ph15080942","article-title":"Antibiotics and carbohydrate-containing drugs targeting bacterial cell envelopes: An overview","volume":"15","author":"Riu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0600","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1128\/AAC.01649-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: Studies of the mode of action in Staphylococcus aureus","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0605","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejmech.2018.10.043","article-title":"1,2,3,4-Tetrahydroisoquinoline\/2H-chromen-2-one conjugates as nanomolar P-glycoprotein inhibitors: Molecular determinants for affinity and selectivity over multidrug resistance associated protein 1","volume":"161","author":"Rullo","year":"2019","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0610","series-title":"Isolation of pathogenic and non-pathogenic microbial stains from different types of sea fish samples and their quality assessment with antibiogram properties","author":"Shahriar","year":"2019"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0615","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1021\/acschembio.9b00977","article-title":"Harnessing \u03b2-lactam antibiotics for illumination of the activity of penicillin-binding proteins in Bacillus subtilis","volume":"15","author":"Sharifzadeh","year":"2020","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0620","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.abd8377","article-title":"Inhibitors of bacterial H(2)S biogenesis targeting antibiotic resistance and tolerance","volume":"372","author":"Shatalin","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0625","article-title":"A comprehensive overview of the antibiotics approved in the last two decades: Retrospects and prospects","volume":"28","author":"Shi","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0630","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41586-022-05019-y","article-title":"Teixobactin kills bacteria by a two-pronged attack on the cell envelope","volume":"608","author":"Shukla","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0635","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clinical Microbiology Reviews"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0640","series-title":"Polypharmacology in drug discovery","first-page":"167","article-title":"Polypharmacology as an emerging trend in antibacterial discovery","author":"Silver","year":"2012"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0645","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/cgf.13158","article-title":"Geometric detection algorithms for cavities on protein surfaces in molecular graphics: A survey","volume":"36","author":"Sim\u00f5es","year":"2017","journal-title":"Computer Graphics Forum"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0650","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1016\/j.bmcl.2014.06.053","article-title":"Confronting the challenges of discovery of novel antibacterial agents","volume":"24","author":"Singh","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0655","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10061239","article-title":"Targeting the holy triangle of quorum sensing, biofilm formation, and antibiotic resistance in pathogenic bacteria","volume":"10","author":"Sionov","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113768","article-title":"Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy","volume":"225","author":"Soltan","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0665","series-title":"Multi-target drug design using chem-bioinformatic approaches","first-page":"459","article-title":"Computational methods for multi-target drug designing against mycobacterium tuberculosis","author":"Srivastava","year":"2019"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0670","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s12098-019-03180-3","article-title":"Antibiotic resistance \u2014 A cause for reemergence of infections","volume":"87","author":"Subramaniam","year":"2020","journal-title":"The Indian Journal of Pediatrics"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0675","doi-asserted-by":"crossref","first-page":"FDD73","DOI":"10.4155\/fdd-2022-0001","article-title":"Multitargeted anti-infective drugs: Resilience to resistance in the antimicrobial resistance era","volume":"4","author":"Suckling","year":"2022","journal-title":"Future Drug Discovery"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0680","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3389\/fmicb.2018.02066","article-title":"Antibiotics, resistome and resistance mechanisms: A bacterial perspective","volume":"9","author":"Sultan","year":"2018","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0685","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.659845","article-title":"Macrocycle-antibiotic hybrids: A path to clinical candidates","volume":"9","author":"Surur","year":"2021","journal-title":"Frontiers in Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0690","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00207-19","article-title":"Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations","volume":"63","author":"Szili","year":"2019","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0695","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00205","article-title":"Multi-target pharmacology: Possibilities and limitations of the \u201cskeleton key approach\u201d from a medicinal chemist perspective","volume":"6","author":"Talevi","year":"2015","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0700","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/13816128113199990470","article-title":"Network pharmacology strategies toward multi-target anticancer therapies: From computational models to experimental design principles","volume":"20","author":"Tang","year":"2014","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0705","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41594-020-00532-y","article-title":"Structural insights into outer membrane asymmetry maintenance in gram-negative bacteria by MlaFEDB","volume":"28","author":"Tang","year":"2021","journal-title":"Nature Structural & Molecular Biology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0710","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26092671","article-title":"New antibiotics for multidrug-resistant bacterial strains: Latest research developments and future perspectives","volume":"26","author":"Terreni","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0715","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","article-title":"Drug combinations: A strategy to extend the life of antibiotics in the 21st century","volume":"17","author":"Tyers","year":"2019","journal-title":"Nature Reviews. Microbiology"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0720","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"Journal of Infection and Public Health"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0725","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.3390\/molecules25204723","article-title":"Merging ligand-based and structure-based methods in drug discovery: An overview of combined virtual screening approaches","volume":"25","author":"V\u00e1zquez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0730","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1021\/mp800102c","article-title":"Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors","volume":"6","author":"Vi\u00f1a","year":"2009","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0735","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejmech.2019.02.076","article-title":"Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer\u2019s disease","volume":"169","author":"Wang","year":"2019","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0740","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1126\/science.abn4213","article-title":"Bioinformatic prospecting and synthesis of a bifunctional lipopeptide antibiotic that evades resistance","volume":"376","author":"Wang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0745","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1039\/C8SC02616E","article-title":"Probing key elements of teixobactin-lipid II interactions in membranes","volume":"9","author":"Wen","year":"2018","journal-title":"Chemical Science"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112931","article-title":"Polypharmacological drug actions of recently FDA approved antibiotics","volume":"209","author":"Wetzel","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0755","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/d41573-022-00102-5","article-title":"Novel antibiotics from bacterial blueprints","volume":"21","author":"Willson","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0760","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1021\/id500052s","article-title":"Solving the antibiotic crisis","volume":"1","author":"Wright","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0765","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","article-title":"Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy","volume":"16","author":"Wright","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105921","article-title":"Applications of \u201clinkers\u201d in fragment-based drug design","volume":"127","author":"Wu","year":"2022","journal-title":"Bioorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0775","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/med.21946","article-title":"Bacterial proton motive force as an unprecedented target to control antimicrobial resistance","volume":"43","author":"Yang","year":"2023","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0780","series-title":"Cheminformatics, QSAR and machine learning applications for novel drug development","first-page":"637","article-title":"Chapter 25 - Tools and software for computer-aided drug design and discovery","author":"Yang","year":"2023"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.116405","article-title":"Synthesis, characterization and application of Co\/Co3O4 nanocomposites as an effective photocatalyst for discoloration of organic dye contaminants in wastewater and antibacterial properties","volume":"337","author":"Yousefi","year":"2021","journal-title":"Journal of Molecular Liquids"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0790","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0795","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/antibiotics11091215","article-title":"The mechanism of bacterial resistance and potential bacteriostatic strategies","volume":"11","author":"Zhang","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0800","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acs.jcim.6b00491","article-title":"Computational multitarget drug design","volume":"57","author":"Zhang","year":"2017","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0805","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8030425","article-title":"Quorum-sensing regulation of antimicrobial resistance in bacteria","volume":"8","author":"Zhao","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0810","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational design of multitarget-directed ligands: Strategies and emerging paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108550_bb0815","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1039\/C6NP00025H","article-title":"The evolution of genome mining in microbes - a review","volume":"33","author":"Ziemert","year":"2016","journal-title":"Natural Product Reports"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823002140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823002140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:34:46Z","timestamp":1759012486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823002140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":163,"alternative-id":["S0163725823002140"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108550","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multitarget antibacterial drugs: An effective strategy to combat bacterial resistance","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108550"}}